Flutemetamol is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate ?-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer?s disease (AD) or other causes of cognitive decline. A negative Vizamyl scan indicates sparse to no neuritic plaques, and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient?s cognitive impairment is due to AD. A positive Vizamyl scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions, as well as older people with normal cognition. Vizamyl is an adjunct to other diagnostic evaluations. Limitations of Use:
– A positive Vizamyl scan does not establish a diagnosis of AD or other cognitive disorder
– Safety and effectiveness of Vizamyl have not been established for: o Predicting development of dementia or other neurological condition
o Monitoring responses to therapies. Flutemetamol was developed by University Of Pittsburgh.
The API has now reached off-patent status, after being launched in 2013.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Flutemetamol and many others, contact info@pharmacheminvestor.com